M. Jahangir Alam, PhD
University of Houston
H-index: 34
North America-United States
Top articles of M. Jahangir Alam, PhD
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile | Antimicrobial Agents and Chemotherapy | Eugénie Bassères Taryn A Eubank Khurshida Begum M Jahangir Alam Jinhee Jo | 2024/2/16 |
Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers | The Journal of Infectious Diseases | Jinhee Jo Chenlin Hu Khurshida Begum Weiqun Wang Thanh M Le | 2024/1/15 |
2063. Elucidating the Gram-Positive Selective Spectrum Activity of Ibezapolstat; Secondary Analysis from the phase 2a trial | Open Forum Infectious Diseases | Chris Lancaster Jacob McPherson M Jahangir Alam Khurshida Begum Md Ekramul Karim | 2023/12 |
Comparison of Risk Stratification Approaches to Identify Patients with Clostridioides difficile Infection at Risk for Multidrug-Resistant Organism Gut Microbiota … | Infectious Diseases and Therapy | Evan J Zasowski Maryam Ali Ada Anugo Nayle Ibragimova Kierra M Dotson | 2023/8 |
The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic | Antimicrobial Agents and Chemotherapy | Clive S Mason Tim Avis Chenlin Hu Nabeetha Nagalingam Manikhandan Mudaliar | 2023/5/17 |
Fusobacteria behaving badly: Masquerading strains of strictly anaerobic Escherichia coli misidentified due to the deletion of the hemB gene | Anaerobe | Bradley T Endres Eugenie Basseres Diane M Citron Kerin L Tyrrell Khurshida Begum | 2023/2/1 |
682. Novel rpoB mutations and trends in clinical Clostridioides difficile isolates with reduced fidaxomicin susceptibility | Open Forum Infectious Diseases | Anne J Gonzales-Luna Thanh Le Taryn A Eubank Md Ekramul Karim M Jahangir Alam | 2023/12 |
Isolation and characterisation of carbapenem-resistant Pseudomonas aeruginosa from hospital environments in tertiary care hospitals in Dhaka, Bangladesh | Journal of Global Antimicrobial Resistance | Karabi Saha Nayel Daneesh Kabir Md Rayhanul Islam Mohammed Badrul Amin Kazi Injamamul Hoque | 2022/9/1 |
Functional and metagenomic evaluation of ibezapolstat for early evaluation of anti-recurrence effects in Clostridioides difficile infection | Antimicrobial Agents and Chemotherapy | Jacob McPherson Chenlin Hu Khurshida Begum Weiqun Wang Chris Lancaster | 2022/8/16 |
Multi-country surveillance of Clostridioides difficile demonstrates high prevalence of spores in non-healthcare environmental settings | Anaerobe | Jinhee Jo Anne J Gonzales-Luna Chris K Lancaster Jacob K McPherson Khurshida Begum | 2022/6/1 |
Draft genome sequence data of a clinical Enterococcus faecalis isolate SHH039 from a patient with cholecystitis from a tertiary care hospital in Sabah, Malaysia | Data in Brief | Nur Nashyiroh Izayati Mastor Vijay Kumar Subbiah Wan Nazirah Wan Abu Bakar Khurshida Begum M Jahangir Alam | 2022/4/1 |
521. Investigating the Gram-Positive Selective Spectrum of Ibezapolstat, a First-in-Class DNA Polymerase IIIC (Pol IIIC) Inhibitor | Open Forum Infectious Diseases | M Jahangir Alam Khurshida Begum Md Ekramul Karim Chenlin Hu Eugenie Basseres | 2022/12/1 |
Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial. | Clinical Infectious Diseases | Kevin W Garey Jacob McPherson An Q Dinh Chenlin Hu Jinhee Jo | 2022/10/1 |
Visualization of fidaxomicin association with the exosporium layer of Clostridioides difficile spores | Anaerobe | Eugénie Bassères Bradley T Endres Nicolás Montes-Bravo Nicolás Pérez-Soto Tasnuva Rashid | 2021/6/1 |
Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains | Anaerobe | Masaad Saeed Almutairi Anne J Gonzales-Luna Faris S Alnezary Saad B Fallatah M Jahangir Alam | 2021/12/1 |
1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile | Open Forum Infectious Diseases | Clive Mason Tim Avis Chris Coward David Powell Esther Duperchy | 2021/11 |
701. An Open-label Phase 2a Study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS) Antibiotic, for Patients with Clostridioides difficile Infection | Open Forum Infectious Diseases | Kevin W Garey Khurshida Begum Chenlin Hu Weiqun Wang Chris Lancaster | 2021/11 |
Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection | Open forum infectious diseases | Anne J Gonzales-Luna Abiola O Olaitan Wan-Jou Shen Aditi Deshpande Travis J Carlson | 2021/8/1 |
Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation | Anaerobe | Anne J Gonzales-Luna Jennifer K Spinler Numan Oezguen Md Abdul Wadud Khan Heather A Danhof | 2021/8/1 |
Molecular epidemiology of toxigenic Clostridioides difficile isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh | Anaerobe | Amelia K Sofjan Mohammad Aminul Islam Kakali Halder Nayel D Kabir Ahmed Abu Saleh | 2020/2/1 |
Co-Authors
